Uses of Santabin

Santabin drug is indicated in the treatment of cancer of the breast, pancreas, bladder... However, during the treatment Santabin drug may cause some unwanted side effects. Therefore, before using Santabin, patients need to carefully study information and follow the doctor's instructions.

Santabin belongs to the group of anti-cancer drugs and acts on the immune system. The drug is prepared in the form of lyophilized powder for injection, packing: Box of 1 vial. The ingredient Gemcitabine 200mg (as Gemcitabine hydrochloride) in Santabin has the generic international name 2'-deoxy-2', 2'-difluorocytidine monohydrochloride, used in the treatment of cancer.

Santabin drug is indicated in the treatment of the following diseases:
Non-small cell lung cancer; Pancreatic adenocarcinoma; Pancreatic cancer resistant to 5-FU; Bladder cancer; Breast cancer; Treatment of advanced small cell lung, ovarian, and breast carcinomas; Treatment of advanced bladder cancer.

Dosage for non-small cell lung cancer:
As monotherapy: In adults, the recommended dose of Santabin is 1,000 mg/m2 intravenously over 30 minutes. Repeat this dose once a week for 3 weeks, then stop for 1 week and then repeat this 4-week cycle. Reduce the dose of Santabin based on the degree of toxicity occurring in the patient. Combination use: In adults, Santabin was studied in combination with cisplatin according to the following 2 regimens: 3-week regimen: Gemcitabin 1,250 mg/m2, intravenous infusion over 30 minutes on days 1 and 8 of a cycle 21 day period. The 3-week regimen used Cisplatin 75-100mg/m2 on day 1 of a 21-day cycle, before Gemcitabine was given. The dose of Gemcitabid may be reduced based on the degree of toxicity in each patient. 4-week regimen: Use active ingredient Gemcitabine 1,000mg/m2, intravenous infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. The 4-week regimen used Cisplatin 75-100mg/m2 on day 1 of a 28-day cycle, after Gemcitabine was administered. The dose of Gemcitabi may be reduced based on the degree of toxicity in each patient. Santabin dose for pancreatic cancer:
In adults, the recommended dose of Gemcitabine is 1,000 mg/m2 intravenously over 30 minutes. Repeat this dose once a week for 7 weeks, then stop for 1 week. Continue this dose once a week for 3 weeks, then stop for 1 week. And so repeat this 4-week cycle. The dose of Gemcitabine should be reduced based on the degree of toxicity occurring in the patient. Santabin dose in the treatment of bladder cancer:
Monotherapy: In adults, the recommended dose of Gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Then repeat this 4-week cycle. Combination Use: In adults, when combined with cisplatin, the recommended dose of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Cisplatin at the recommended dose of 70 mg/m2 on day 1 after gemcitabine or on day 2 of each 28-day cycle. Then repeat this 4-week cycle. Dose reduction is based on the degree of toxicity occurring in the patient. Dose of Santabin for breast cancer treatment:
In adults, Gemcitabine is used in combination with Paclitaxel, Gemcitabine (1,250mg/m2) for intravenous infusion over 30 minutes, on days 1 and 8 of a 21-day cycle. Paclitaxel (175 mg/m2) was given as an intravenous infusion over 3 hours after gemcitabine administration. The above dosage of Santabin is for reference only. The specific dose of Santabin will depend on the condition and the progression of the disease. To get the right dose of Santabin, patients need to consult their doctor or pharmacist.

Santabin is contraindicated in patients with hypersensitivity to Gemcitabine or its components.

When using Santabin, you may experience the following side effects:
Myelosuppression; Abnormal liver enzymes; Vomiting and nausea. Usually these side effects go away when you stop taking Santabin. However, in order to ensure health safety, during treatment, if any abnormal symptoms appear due to the use of Santabin drug, the patient should notify the doctor for appropriate treatment. fit.

Need to use Santabin with caution in the following cases:
Patients with bone marrow failure; Patients with kidney and liver failure; Closely monitor patients taking Gemcitabine. It is necessary to perform subclinical tests to monitor the patient's condition; Avoid administering Santabin to pregnant or lactating women as it may be toxic to the fetus or nursing infant. To avoid unwanted interactions when using Santabin, patients should inform their doctor/pharmacist of all medications, supplements, vitamins they are taking. Above is all information about the drug Santabin has what effect, dosage and note when using. To ensure safety for your health and maximize the effectiveness of your treatment, you need to take Santabin exactly as directed by your doctor.